Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective strategy to identify relatives of type 1 diabetic patients with a high and age-independent progression rate to clinical onset.

Frans Gorus; Eric Balti Vounsia; Ilse Vermeulen; Simke Demeester; Annelien Van Dalem; Olivier Costa; H. Dorchy; S. Tenoutasse; T. Mouraux; C. De Block; Pieter Gillard; Katelijn Decochez; J. Wenzlau; J. Hutton; Daniel Pipeleers; Ilse Weets; Belgian Diabetes Registry

Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective strategy to identify relatives of type 1 diabetic patients with a high and age-independent progression rate to clinical onset.

Frans Gorus, Eric Balti Vounsia, Ilse Vermeulen, Simke Demeester, Annelien Van Dalem, Olivier Costa, H. Dorchy, S. Tenoutasse, T. Mouraux, C. De Block, Pieter Gillard, Katelijn Decochez, J. Wenzlau, J. Hutton, Daniel Pipeleers, Ilse Weets, Belgian Diabetes Registry

Research output: Contribution to journal › Article › peer-review

41 Citations (Scopus)

Abstract

In first-degree relatives of type 1 diabetic patients, we investigated whether diabetes risk assessment solely based on insulinoma antigen 2 (IA-2) and zinc transporter 8 (ZnT8) antibody status (IA-2A, respectively, ZnT8A) is as effective as screening for three or four autoantibodies [antibodies against insulin (IAA), glutamate decarboxylase 65?kDa (GAD) glutamate decarboxylase autoantibodies (GADA) and IA-2A with or without ZnT8A] in identifying children, adolescents and adults who progress rapidly to diabetes (within 5 years). Antibodies were determined by radiobinding assays during follow-up of 6444 siblings and offspring aged 0-39 years at inclusion and recruited consecutively by the Belgian Diabetes Registry. We identified 394 persistently IAA(+) , GADA(+) , IA-2A(+) and/or ZnT8A(+) relatives (6·1%). After a median follow-up time of 52 months, 132 relatives developed type 1 diabetes. In each age category tested (0-9, 10-19 and 20-39 years) progression to diabetes was significantly quicker in the presence of IA-2A and/or ZnT8A than in their joint absence (P?

Original language	English
Pages (from-to)	82-90
Number of pages	9
Journal	Clin Exp Immunol
Volume	171
Publication status	Published - 2013

Keywords

IA-2 antibodies, prediction, prevention
type 1 diabetes
zinc transporter 8 antibodies

Access to Document

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2249.2012.04675.x/epdf

Fingerprint

Dive into the research topics of 'Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective strategy to identify relatives of type 1 diabetic patients with a high and age-independent progression rate to clinical onset.'. Together they form a unique fingerprint.

Cite this

Gorus, F., Balti Vounsia, E., Vermeulen, I., Demeester, S., Van Dalem, A., Costa, O., Dorchy, H., Tenoutasse, S., Mouraux, T., De Block, C., Gillard, P., Decochez, K., Wenzlau, J., Hutton, J., Pipeleers, D., Weets, I., & Belgian Diabetes Registry (2013). Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective strategy to identify relatives of type 1 diabetic patients with a high and age-independent progression rate to clinical onset. Clin Exp Immunol, 171, 82-90. http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2249.2012.04675.x/epdf

@article{227b69b456024707abd66682e036972d,

title = "Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective strategy to identify relatives of type 1 diabetic patients with a high and age-independent progression rate to clinical onset.",

abstract = "In first-degree relatives of type 1 diabetic patients, we investigated whether diabetes risk assessment solely based on insulinoma antigen 2 (IA-2) and zinc transporter 8 (ZnT8) antibody status (IA-2A, respectively, ZnT8A) is as effective as screening for three or four autoantibodies [antibodies against insulin (IAA), glutamate decarboxylase 65?kDa (GAD) glutamate decarboxylase autoantibodies (GADA) and IA-2A with or without ZnT8A] in identifying children, adolescents and adults who progress rapidly to diabetes (within 5 years). Antibodies were determined by radiobinding assays during follow-up of 6444 siblings and offspring aged 0-39 years at inclusion and recruited consecutively by the Belgian Diabetes Registry. We identified 394 persistently IAA(+) , GADA(+) , IA-2A(+) and/or ZnT8A(+) relatives (6·1%). After a median follow-up time of 52 months, 132 relatives developed type 1 diabetes. In each age category tested (0-9, 10-19 and 20-39 years) progression to diabetes was significantly quicker in the presence of IA-2A and/or ZnT8A than in their joint absence (P?",

keywords = "IA-2 antibodies, prediction, prevention, type 1 diabetes, zinc transporter 8 antibodies",

author = "Frans Gorus and {Balti Vounsia}, Eric and Ilse Vermeulen and Simke Demeester and {Van Dalem}, Annelien and Olivier Costa and H. Dorchy and S. Tenoutasse and T. Mouraux and {De Block}, C. and Pieter Gillard and Katelijn Decochez and J. Wenzlau and J. Hutton and Daniel Pipeleers and Ilse Weets and {Belgian Diabetes Registry}",

year = "2013",

language = "English",

volume = "171",

pages = "82--90",

journal = "Clin Exp Immunol",

issn = "0009-9104",

publisher = "Wiley-Blackwell",

}

Gorus, F , Balti Vounsia, E, Vermeulen, I, Demeester, S , Van Dalem, A, Costa, O, Dorchy, H, Tenoutasse, S, Mouraux, T, De Block, C, Gillard, P, Decochez, K, Wenzlau, J, Hutton, J, Pipeleers, D , Weets, I & Belgian Diabetes Registry 2013, 'Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective strategy to identify relatives of type 1 diabetic patients with a high and age-independent progression rate to clinical onset.', Clin Exp Immunol, vol. 171, pp. 82-90. <http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2249.2012.04675.x/epdf>

Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective strategy to identify relatives of type 1 diabetic patients with a high and age-independent progression rate to clinical onset. / Gorus, Frans ; Balti Vounsia, Eric; Vermeulen, Ilse et al.
In: Clin Exp Immunol, Vol. 171, 2013, p. 82-90.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective strategy to identify relatives of type 1 diabetic patients with a high and age-independent progression rate to clinical onset.

AU - Gorus, Frans

AU - Balti Vounsia, Eric

AU - Vermeulen, Ilse

AU - Demeester, Simke

AU - Van Dalem, Annelien

AU - Costa, Olivier

AU - Dorchy, H.

AU - Tenoutasse, S.

AU - Mouraux, T.

AU - De Block, C.

AU - Gillard, Pieter

AU - Decochez, Katelijn

AU - Wenzlau, J.

AU - Hutton, J.

AU - Pipeleers, Daniel

AU - Weets, Ilse

AU - Belgian Diabetes Registry

PY - 2013

Y1 - 2013

N2 - In first-degree relatives of type 1 diabetic patients, we investigated whether diabetes risk assessment solely based on insulinoma antigen 2 (IA-2) and zinc transporter 8 (ZnT8) antibody status (IA-2A, respectively, ZnT8A) is as effective as screening for three or four autoantibodies [antibodies against insulin (IAA), glutamate decarboxylase 65?kDa (GAD) glutamate decarboxylase autoantibodies (GADA) and IA-2A with or without ZnT8A] in identifying children, adolescents and adults who progress rapidly to diabetes (within 5 years). Antibodies were determined by radiobinding assays during follow-up of 6444 siblings and offspring aged 0-39 years at inclusion and recruited consecutively by the Belgian Diabetes Registry. We identified 394 persistently IAA(+) , GADA(+) , IA-2A(+) and/or ZnT8A(+) relatives (6·1%). After a median follow-up time of 52 months, 132 relatives developed type 1 diabetes. In each age category tested (0-9, 10-19 and 20-39 years) progression to diabetes was significantly quicker in the presence of IA-2A and/or ZnT8A than in their joint absence (P?

AB - In first-degree relatives of type 1 diabetic patients, we investigated whether diabetes risk assessment solely based on insulinoma antigen 2 (IA-2) and zinc transporter 8 (ZnT8) antibody status (IA-2A, respectively, ZnT8A) is as effective as screening for three or four autoantibodies [antibodies against insulin (IAA), glutamate decarboxylase 65?kDa (GAD) glutamate decarboxylase autoantibodies (GADA) and IA-2A with or without ZnT8A] in identifying children, adolescents and adults who progress rapidly to diabetes (within 5 years). Antibodies were determined by radiobinding assays during follow-up of 6444 siblings and offspring aged 0-39 years at inclusion and recruited consecutively by the Belgian Diabetes Registry. We identified 394 persistently IAA(+) , GADA(+) , IA-2A(+) and/or ZnT8A(+) relatives (6·1%). After a median follow-up time of 52 months, 132 relatives developed type 1 diabetes. In each age category tested (0-9, 10-19 and 20-39 years) progression to diabetes was significantly quicker in the presence of IA-2A and/or ZnT8A than in their joint absence (P?

KW - IA-2 antibodies, prediction, prevention

KW - type 1 diabetes

KW - zinc transporter 8 antibodies

M3 - Article

SN - 0009-9104

VL - 171

SP - 82

EP - 90

JO - Clin Exp Immunol

JF - Clin Exp Immunol

ER -